Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02706691 · ClinicalTrials.gov registry record · Phase 2
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02706691 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 1 participants.
The verdict
NCT02706691, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has returned after a period of improvement. BGJ398 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG BGJ398
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2019-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02706691
The ClinicalTrials.gov registry entry for NCT02706691 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BGJ398 is the first listed.
NCT02706691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02706691 about?
NCT02706691 is a clinical study titled "BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer". This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has returned after a period of improvement. BGJ398 may stop the growth of tum...
What is the current status of trial NCT02706691?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2018-06-01. Estimated completion is 2019-02-11.
What interventions are being tested in trial NCT02706691?
The interventions under investigation include: BGJ398 (DRUG).
Who is sponsoring clinical trial NCT02706691?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.